UBS Group
LSTA icon

UBS Group’s Lisata Therapeutics LSTA Stock Holding History

UBS Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,909
Closed -$9.56K – 10787
2026
Q1 		$9.56K Buy
1,909
+1,038
+119% +$4.29K ﹤0.01% 8431
2025
Q4 		$1.62K Buy
+871
New +$1.94K ﹤0.01% 9517
2025
Q3 		– Sell
-7,069
Closed -$20.5K – 10668
2025
Q2 		$20.5K Buy
7,069
+7,068
+706,800% +$17K ﹤0.01% 8418
2025
Q1 		$2 Hold
1
– – ﹤0.01% 10154
2024
Q4 		$3 Sell
1
-124
-99% -$355 ﹤0.01% 9849
2024
Q3 		$375 Sell
125
-3,584
-97% -$11.3K ﹤0.01% 8970
2024
Q2 		$12.9K Buy
3,709
+3,708
+370,800% +$11.3K ﹤0.01% 7581
2024
Q1 		$3 Sell
1
-235
-100% -$696 ﹤0.01% 9164
2023
Q4 		$645 Buy
236
+93
+65% +$218 ﹤0.01% 8561
2023
Q3 		$306 Buy
143
+142
+14,200% +$394 ﹤0.01% 8598
2023
Q2 		$4 Hold
1
– – ﹤0.01% 8774
2023
Q1 		$3 Sell
1
-5,896
-100% -$19.7K ﹤0.01% 9504
2022
Q4 		$14.9K Buy
5,897
+1,209
+26% +$4.43K ﹤0.01% 8032
2022
Q3 		$22K Buy
4,688
+2,790
+147% +$20.2K ﹤0.01% 7261
2022
Q2 		$15K Buy
1,898
+1,641
+639% +$13.5K ﹤0.01% 7298
2022
Q1 		$3K Sell
257
-3,612
-93% -$41.3K ﹤0.01% 9460
2021
Q4 		$49K Buy
3,869
+3,096
+401% +$47.8K ﹤0.01% 6911
2021
Q3 		$14K Buy
773
+772
+77,200% +$15.1K ﹤0.01% 7588
2021
Q2 		$0 Hold
1
– – ﹤0.01% 9622
2021
Q1 		$0 Sell
1
-432
-100% -$13.1K ﹤0.01% 9279
2020
Q4 		$9K Buy
433
+432
+43,200% +$10.3K ﹤0.01% 7565
2020
Q3 		$0 Hold
1
– – ﹤0.01% 8241
2020
Q2 		$0 Sell
1
-304
-100% -$8.94K ﹤0.01% 8177
2020
Q1 		$8K Buy
305
+139
+84% +$5.39K ﹤0.01% 7078
2019
Q4 		$6K Buy
166
+165
+16,500% +$5.93K ﹤0.01% 7517
2019
Q3 		$0 Hold
1
– – ﹤0.01% 8137
2019
Q2 		$0 Sell
1
-270
-100% -$12K ﹤0.01% 8031
2019
Q1 		$15K Buy
271
+90
+50% +$5.91K ﹤0.01% 6543
2018
Q4 		$10K Buy
181
+180
+18,000% +$12.5K ﹤0.01% 7235
2018
Q3 		$0 Sell
1
-36
-97% -$2.95K ﹤0.01% 8135
2018
Q2 		$4K Sell
37
-63
-63% -$4.44K ﹤0.01% 7556
2018
Q1 		$9K Sell
100
-1
-1% -$69 ﹤0.01% 6938
2017
Q4 		$5K Buy
101
+51
+102% +$2.56K ﹤0.01% 7381
2017
Q3 		$3K Sell
50
-116
-70% -$7.04K ﹤0.01% 7396
2017
Q2 		$11K Sell
166
-53
-24% -$3.74K ﹤0.01% 6718
2017
Q1 		$17K Buy
219
+9
+4% +$624 ﹤0.01% 6263
2016
Q4 		$9K Buy
+210
New +$12.1K ﹤0.01% 6976
2016
Q3 		– Sell
-52
Closed -$5K – 7825
2016
Q2 		$5K Sell
52
-112
-68% -$10.3K ﹤0.01% 7122
2016
Q1 		$19K Buy
164
+124
+310% +$12.2K ﹤0.01% 6242
2015
Q4 		$6K Buy
40
+15
+60% +$2.75K ﹤0.01% 7610
2015
Q3 		$6K Buy
25
+4
+19% +$1K ﹤0.01% 7600
2015
Q2 		$6K Sell
21
-22
-51% -$8.18K ﹤0.01% 7788
2015
Q1 		$16K Buy
43
+25
+139% +$13.6K ﹤0.01% 7207
2014
Q4 		$11K Buy
+18
New +$12.3K ﹤0.01% 8313

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

UBS Group's LSTA Position: Q2 2026 in Review

UBS Group sold out of Lisata Therapeutics (LSTA) in Q2 2026, closing a stake of 1,909 shares — an estimated $9.56K sold.

UBS Group first reported a position in LSTA in Q4 2014 and held it in 44 quarters. The position peaked at $49K in Q4 2021. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • UBS Group reported no remaining Lisata Therapeutics position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 1,909 Lisata Therapeutics shares in Q2 2026, an estimated $9.56K.
  • UBS Group first reported a position in Lisata Therapeutics in Q4 2014 and held it in 44 quarters.
  • UBS Group's Lisata Therapeutics position peaked at $49K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.